Botulinum toxin A for the treatment of keloids

G G Gauglitz; D Bureik; Y Dombrowski; T Pavicic; T Ruzicka; J Schauber

doi:10.1159/000342125

Botulinum toxin A for the treatment of keloids

G G Gauglitz, D Bureik, Y Dombrowski, T Pavicic, T Ruzicka, J Schauber

School of Medicine, Dentistry and Biomedical Sciences

Research output: Contribution to journal › Article › peer-review

57 Citations (Scopus)

Abstract

Keloids are the result of excessive scar tissue formation. Besides their poor aesthetic appearance, keloids can be associated with severe clinical symptoms such as pain, itching, and rigidity. Unfortunately, most therapeutic approaches remain clinically unsatisfactory. Recently, injections with botulinum toxin A (BTA) were proposed for the treatment of established keloids in a clinical trial. In this study, we aimed to verify the effects of intralesional BTA for the treatment of therapy-resistant keloids using objective measurements. In addition, the underlying molecular mechanisms were investigated using cultured keloid-derived fibroblasts.

Original language	English
Pages (from-to)	313-8
Number of pages	6
Journal	Skin pharmacology and physiology
Volume	25
Issue number	6
DOIs	https://doi.org/10.1159/000342125
Publication status	Published - 2012

Bibliographical note

Keywords

Actins
Botulinum Toxins, Type A
Cell Proliferation
Collagen
Female
Fibroblasts
Fibronectins
Humans
Injections, Intralesional
Keloid
Laminin
Male
Transforming Growth Factor beta

Access to Document

10.1159/000342125

Cite this

@article{cd3a8d043350475a9fb23fbdd1dfc54d,

title = "Botulinum toxin A for the treatment of keloids",

abstract = "Keloids are the result of excessive scar tissue formation. Besides their poor aesthetic appearance, keloids can be associated with severe clinical symptoms such as pain, itching, and rigidity. Unfortunately, most therapeutic approaches remain clinically unsatisfactory. Recently, injections with botulinum toxin A (BTA) were proposed for the treatment of established keloids in a clinical trial. In this study, we aimed to verify the effects of intralesional BTA for the treatment of therapy-resistant keloids using objective measurements. In addition, the underlying molecular mechanisms were investigated using cultured keloid-derived fibroblasts.",

keywords = "Actins, Botulinum Toxins, Type A, Cell Proliferation, Collagen, Female, Fibroblasts, Fibronectins, Humans, Injections, Intralesional, Keloid, Laminin, Male, Transforming Growth Factor beta",

author = "Gauglitz, {G G} and D Bureik and Y Dombrowski and T Pavicic and T Ruzicka and J Schauber",

note = "Copyright {\textcopyright} 2012 S. Karger AG, Basel.",

year = "2012",

doi = "10.1159/000342125",

language = "English",

volume = "25",

pages = "313--8",

journal = "Skin pharmacology and physiology",

issn = "1660-5535",

publisher = "S. Karger AG",

number = "6",

}

TY - JOUR

T1 - Botulinum toxin A for the treatment of keloids

AU - Gauglitz, G G

AU - Bureik, D

AU - Dombrowski, Y

AU - Pavicic, T

AU - Ruzicka, T

AU - Schauber, J

PY - 2012

Y1 - 2012

N2 - Keloids are the result of excessive scar tissue formation. Besides their poor aesthetic appearance, keloids can be associated with severe clinical symptoms such as pain, itching, and rigidity. Unfortunately, most therapeutic approaches remain clinically unsatisfactory. Recently, injections with botulinum toxin A (BTA) were proposed for the treatment of established keloids in a clinical trial. In this study, we aimed to verify the effects of intralesional BTA for the treatment of therapy-resistant keloids using objective measurements. In addition, the underlying molecular mechanisms were investigated using cultured keloid-derived fibroblasts.

AB - Keloids are the result of excessive scar tissue formation. Besides their poor aesthetic appearance, keloids can be associated with severe clinical symptoms such as pain, itching, and rigidity. Unfortunately, most therapeutic approaches remain clinically unsatisfactory. Recently, injections with botulinum toxin A (BTA) were proposed for the treatment of established keloids in a clinical trial. In this study, we aimed to verify the effects of intralesional BTA for the treatment of therapy-resistant keloids using objective measurements. In addition, the underlying molecular mechanisms were investigated using cultured keloid-derived fibroblasts.

KW - Actins

KW - Botulinum Toxins, Type A

KW - Cell Proliferation

KW - Collagen

KW - Female

KW - Fibroblasts

KW - Fibronectins

KW - Humans

KW - Injections, Intralesional

KW - Keloid

KW - Laminin

KW - Male

KW - Transforming Growth Factor beta

U2 - 10.1159/000342125

DO - 10.1159/000342125

M3 - Article

C2 - 22948093

VL - 25

SP - 313

EP - 318

JO - Skin pharmacology and physiology

JF - Skin pharmacology and physiology

SN - 1660-5535

IS - 6

ER -

Botulinum toxin A for the treatment of keloids

Abstract

Bibliographical note

Keywords

Access to Document

Fingerprint

Cite this